جستجوی مقالات مرتبط با کلیدواژه « Atypical antipsychotic » در نشریات گروه « پزشکی »

Patients with schizophrenia receiving antipsychotic drugs are highly at risk of metabolic disorders such as weight gain، dyslipidemia، and insulin resistance. This study was designed to compare the effect of atypical and conventional antipsychotics on lipid profile.

128 patients with schizophrenia were divided in two groups. One of the groups received one type of atypical antipsychotic drugs while the other got one type of conventional ones. None of the groups had used any other antipsychotic drugs during the past year. Demographic data and food frequency questionnaire were completed by each participant. Serum triglyceride، total cholesterol (TC)، high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterols، and apolipoprotein A and B (Apo A and B) were recorded. Student’s t test was used for statistical analysis.

The two groups were similar in age، gender، duration of illness، period of drug consumption، and age at onset of illness. Patients in the atypical group used clozapine and risperidone (46. 9%) more than olanzapine; while in the conventional group، 81. 3% of patients used phenothiazines. Our data showed a significantly higher mean in TC (P = 0. 01)، LDL (P = 0. 03)، and Apo B (P = 0. 01) in conventional group.

In patients with schizophrenia، lipid profile was higher in both atypical and conventional antipsychotic users، especially in conventional drug users.

Antipsychotic drugs are the cornerstone of schizophrenia treatment. Glucoregulatory abnormalities have been associated with the use of antipsychotic medications. There are some reports of weight gain and glucose intolerance in patients with schizophrenia receiving atypical antipsychotic medications. The purpose of this study is to compare the effect of various antipsychotic therapies on glycemic control in patients with schizophrenia.

Eighty-one patients with schizophrenia were enrolled in the study and underwent glucose-tolerance test. Patients were divided in to two groups، with one group (n=43) receiving typical and the other group (n=38) receiving atypical medication. Demographical and historical data were collected with a questionnaire.

There was a marginally significant difference in the first hour glucose level between typical and atypical drugs (mean 132. 12 vs. 151. 76، respectively، p=0. 07). Also، marginal significant difference was present comparing the first hour glucose level between typical antipsychotics and clozapine consumers (mean 132. 12 vs. 153. 67، p=0. 06). This difference was not present when typical antipsychotics were compared with risperidone (mean 132. 12 vs. 149. 41، p=0. 230). Fasting blood sugar and second- hour glucose tolerance results did not show a statistically significant difference. The increased GTT of the first hour blood sugar in patients who received clozapin may indicate the early stages of insulin resistance in this group.

This study suggests that patients under atypical antipsychotic treatment are more vulnerable to diabetes mellitus (DM). Across atypical medications; we observed a greater glycemic effect from clozapin compared to risperidone.